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CASE REPORT
Fexofenadine-Induced Urticaria
Sang Woo Lee, M.D., Ji Yeon Byun, M.D., You Won Choi, M.D., Ki Bum Myung, M.D., 
Hae Young Choi, M.D.
Department of Dermatology, School of Medicine, Ewha Womans University, Seoul, Korea
Fexofenadine (Allegra
Ⓡ 180) is a second-generation anti-
histamine. It is widely used as anti-allergic drug, which 
suppresses various allergic reactions mediated by hista-
mines. A few cases of H1-antihistamine-induced urticaria 
have been reported. Herein, we report a rare case of 
fexofenadine-induced urticaria which was confirmed by a 
prick test, oral provocation test, and flow cytometry 
assisted-basophil activation test. (Ann Dermatol 23(S3) S329
∼S332, 2011)
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INTRODUCTION
H1 antihistamines are widely used and probably most 
frequently used in allergic diseases. Topical application of 
antihistamines commonly leads to sensitization for patients; 
however, skin reactions provoked by systemic admini-
stration of antihistamines have been very rare
1,2. Although 
the rate of urticaria induced by antihistamines has been 
rare, its relevance should not be ignored. To our know-
ledge, only 16 cases of H1 antihistamine-induced urticaria 
have been reported in the literature
2-13, and it has never 
been reported in Korea. Herein, we report a rare case of 
fexofenadine-induced urticaria.
CASE REPORT
A 69-year-old man first visited at our dermatology depart-
ment with a 10 month history of pruritic papules on his 
face and scalp in January 2009. With the diagnosis of 
allergic contact dermatitis, he had been receiving treat-
ment with levocetirizine (Xyzal
Ⓡ) the previous week with 
no improvement. During the first three days of fexo-
fenadine (Allegra 180
Ⓡ) supplementation, he experienced 
episodes of itchy hives over his body about two hours 
after receiving 180 mg of fexofenadine in addition to 5 mg 
of levocetirizine. After ceasing the fexofenadine for two 
days, the symptoms disappeared; however, it recurred 
after rechallenging with the same drugs the next day. 
Personal and family histories were not remarkable. 
Dermatological examination revealed pruritic wheals over 
his body. He was treated with oral corticosteroids for 
three days and subsequently, levocetirizine was continued 
to control allergic contact dermatitis. No further wheals 
were observed. Three months later, prick tests with 
fexofenadine  dilutions of 0.01%, 0.05% and 0.1% 
(powder dissolved in 0.9% NaCl) were performed. After 
ten minutes, a wheal developed  at the  0.1% fexofe-
nadine site (Fig. 1). Patch tests with various classes of 
antihistamines including fexofenadine, terfenadine, and 
levocetirizine were carried out; however, but the results 
were all negative (powdered in petrolatum with concen-
trations of 1%, 5%, and 10%, data are not shown). 
To confirm the diagnosis, oral provocation tests were 
performed. Increasing doses were administered at 1-hour 
intervals starting with the half-dose. Urticarial eruptions 
developed over the body one hour after taking the total 
dose (180 mg) of fexofenadine (Fig. 2). Flow cytometry- 
assisted basophil activation test with the patient’s blood 
showed positive results (Fig. 3). SW Lee, et al
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Fig. 1. (A) A prick test was done on
the forearm with saline as a negative
control, and 0.01%, 0.05%, 0.1% 
fexofenadine. (B) Fifteen minutes 
later, a wheal developed at the 0.1%
fexofenadine-provoked area. 
Fig. 2. (A) Urticarial eruptions with itching sensation developed about 1 hour after provocation with a 180 mg dose of fexofenadine.
(B) Close-up view.
DISCUSSION
Fexofenadine is an active metabolite of terfenadine, and is 
a second generation antihistamine derived from piperi-
dines. Adverse reactions to antihistamines have been rare, 
and second generation antihistamines are also more 
selective and less sedative. The most common adverse 
reactions related to fexofenadine have been headache, 
dizziness, daytime drowsiness, nausea, among others at a 
rate of more than 1%, and it has been very rarely reported 
to cause hypersensitivity
14. Cutaneous lesions have been 
demonstrated to appear as urticaria; maculo-papular, 
morbilliform, and scarlatiniform eruptions; erythema multi-
forme; photosensitivity; fixed eruptions; and anaphylactic 
shock
1.
Sixteen cases of antihistamine-induced skin reaction in the 
form of urticaria have been reported in the literature 
(Table 1), with  cetirizine being the most common causal 
drug, and diphenhydramine, prophenpyridamine, lora-
tadine, mequitazine, levocetirizine, ebastine, bepotastine, 
hydroxyzine, olopatazine and dexchlorpheniramine also 
have been reported to cause urticarial reactions. Fexo-
fenadine has been identified as the eliciting drug in three 
previous cases
6,11,12. 
In most cases of antihistamine-induced urticaria, oral pro-
vocation test and prick tests were performed. Oral pro-
vocation test results were positive in all cases; however, 
prick test results were positive in only five cases including 
our own
2,4,9,13. 
The mechanism of antihistamine-induced urticaria has Fexofenadine-Induced Urticaria
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Fig. 3. In the flow cytometry-assisted basophil activation test, 4.57% and 22.77% of basophils were activated in negative and positive
controls, respectively (A, B). When a challenge with fexofenadine at 2.5 mg and 1.25 mg was done, 44.73% and 10.58% of basophils
were activated, respectively (C, D). UL: upper left, UR: upper right, LL: lower left, LR: lower right.
Table 1. Reported cases of urticaria induced by antihistamines in English literature
References Age/Sex Clinical findings Causative drug Provocation
test Patch test Prick/intradermal/
scratch test
Epstein (1949)
3 36/F Urticaria, MP Diphenhydramine, ND ＋ −
 Prophenpyridamine
Stingeni et al. (1997)
2 70/F Urticaria, MP Cetirizine ND ＋＋
Barranco et al. (1998)
4 42/F Urticaria, Diphenhydramine ＋  − ＋
 Anaphylaxis
Karamfilov et al. (1999)
5 29/F Urticaria Cetirizine ＋  −−
Demoly et al. (2000)
6 57/F Urticaria Fexofenadine, Loratazine, ＋ −−
 Mequitazine Cetirizine
Calista et al. (2001)
7 42/F Urticaria Cetirizine ＋  ND −
Tella et al. (2002)
8 32/F Urticaria Cetirizine ＋ ND −
Schröter et al. (2002)
9 36/F Urticaria Cetirizine ＋  ＋ ＋
Kränke and 33/F Urticaria Levocetirizine ＋  ND −
 Mayr-Kanhäuser (2005)
10
Gonzälez de 30/F Urticaria Ebastine,  ＋  −   −*
 Olano et al. (2006)
11  Loratadine Cetirizine,
 Fexofenadine
Inomata et al. (2009)
12 34/F Urticaria, Fexofenadine, ＋  ND −
 Anaphylaxis  Bepotastine Loratadine,
 Ebastine Hydroxyzine,
 Cetirizine Olopatazine
Rodríquez del Río 36/M Urticaria Hydroxyzine ＋ − ND
 et al. (2009)
13 20/F Urticaria Loratadine, Cetirizine ＋ ND −
30/F Urticaria Dexchlorpheniramine, ＋ ND −
 Hydroxizine
57/M Urticaria Angioedem Mequitazine, ＋ ND −
 Ebastine
36/F Urticaria Hydroxyzine,   ＋
† − +
 Levocetirizine Ebastine
Our case 69/M Urticaria Fexofenadine ＋ − +
F: female, M: male, MP: maculo-papular eruption, ND: not done. *Positive reactions to several other antihistamines were observed 
on prick tests, but the results were negative to ebastine, loratadine, cetirizine and fexofenadine. 
†Positive reactions to dexchlo-
rpheniramine, mizolastine, desloratadine, rupatadine and azelastine were observed in the provocation tests, but these drugs were
negative on prick tests.SW Lee, et al
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remained controversial. In some reported cases, it has 
been noted as a type I IgE-mediated hypersensitivity reac-
tion because of a suggestive clinical history and positive 
reaction on prick and intradermal tests
4,12,13. In contrast, 
other reports have shown negative results to prick tests 
with the causative drugs, suggesting a non-immunologic 
reaction. Possible mechanisms include a Type IV hyper-
sensitivity reaction, non-specific mast cell degranulation 
or activation of the alternative pathway of the complement 
system
7, or an intolerance reaction
9,10. 
The basophil activation test is a functional in vitro test that 
has been used to investigate the cause of allergic reac-
tions. Basophils are now considered equivalent to tissue 
mast cells since they play, by themselves, a pivotal role in 
the immediate allergic reaction. Specific population of 
cells can be identified by flow cytometry, which is a 
reliable tool for monitoring basophil activation upon allergen 
challenge by detecting surface expression of degranulation/ 
activation markers, most commonly CD63 and CD203c. 
The flow cytometry-assisted basophil activation test has 
become a standard tool for in vitro diagnosis of immediate 
allergy
15. 
In our patient, a commercialized Flow-CAST kit
Ⓡ (Buehlmann 
laboratories AG, Schoenenbuch, Switzerland) was used 
with fexofenadine at 1.25 mg, 2.5 mg and with stimula-
tion buffer and anti-IgE receptor antibody acting as 
negative and positive controls, respectively. Peripheral 
blood leukocytes were isolated from patient’s whole 
blood samples and primed with stimulation buffer con-
taining interleukin 3. Fexofenadine 1.25 mg and 2.5 mg 
were added and the cells were incubated to mimic the in 
vivo situation where specific IgE bind to the cellular 
surface, are bridged by the allergen, and activate intra-
cellular enzymatic cascades leading to the activation of 
basophils. During the activation, intracellular compounds 
containing the transmembrane protein CD63 fuse to the 
cellular membrane and are expressed to the extracellular 
matrix. Activated basophil levels of fexofenadine-stimulated 
samples were 44.73% and 10.58% (fexofenadine 2.5 mg 
and 1.25 mg respectively) in our patient, which was 
higher than the negative control (4.57) and therefore, the 
test was positive to fexofenadine (Fig. 3). 
Herein, we report an interesting case of urticarial reaction 
due to fexofenadine. The precise mechanism of urticaria 
induced by antihistamines has not yet been elucidated. In 
our case, urticarial eruptions developed one hour after 
taking fexofenadine prick test, oral provocation test with 
fexofenadine, and the basophil activation test showed 
positive results and thus, an underlying immune mecha-
nism cannot be ruled out. Although the allergy tests could 
not distinguish the precise mechanism of the reactions, 
they did demonstrate the causal drugs and allowed for the 
discovery of a well-tolerated drug of the same class. 
Physicians must be aware that, occasionally, drugs used in 
treatment act as the causal agent themselves. 
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